{
    "abstract": "Aim: To evaluate the immunogenicity and safety of a reduced antigen diphtheria-tetanus-acellular pertussis-inactivated poliovirus (dTap-IPVB) vaccine (Boostrix-IPV, GSK) as a pre-school booster in 3\u20134 year old children as compared to dTap-IPVR (Repevax, Sanofi Pasteur), when co-administered with mumps-measles-rubella vaccine (MMRV). Methods: This phase III, open label, randomised study was conducted in the UK between April 2011 and April 2012. Children due their pre-school dTap-IPV booster vaccination were randomised 2:1 to receive one of two different dTap-IPV vaccines (dTap-IPVB or dTap-IPVR) with blood sample for immunogenicity assessment just prior and one month after vaccination. Immune responses to diphtheria, tetanus and polio antigens were compared between the study vaccines (inferential comparison). In the absence of an accepted pertussis correlate of protection, the immunogenicity of dTap-IPVB vaccine against pertussis was compared with historical pertussis efficacy data (inferential comparison). Safety and reactogenicity of both study vaccines were evaluated. Results: 387 children were randomised and 385 vaccinated: 255 in the dTap-IPVB group and 130 in the dTap-IPVR group. Prior to vaccination, \u226576.8% of children had anti-diphtheria and \u226565.5% had anti-tetanus titres above the protection threshold; for pertussis, the pre-vaccination seropositivity rate ranged between 18.1 and 70.6%. Both vaccines were immunogenic with 99.2\u2013100% of children achieving titres above the pre-specified seroprotection/seropositivity thresholds. One serious adverse event not considered as causally related to the study vaccination by the study investigator was reported in the dTap-IPVB group. Conclusion: Non-inferiority of dTap-IPVB to dTap-IPVR was demonstrated. Both vaccines had a clinically acceptable safety and reactogenicity profile when co-administered with MMRV to children 3\u20134 years old. Trial registration: NCT01245049 (ClinicalTrials.gov)",
    "author_highlights": [
        {
            "endOffset": 16367,
            "sentence": "We assessed immunogenicity and safety of dTpa-IPV booster vaccine in 3\u20134 years olds.",
            "startOffset": 16283
        },
        {
            "endOffset": 16442,
            "sentence": "The immunogenicity of dTpa-IPV (Boostrix-IPV) was non-inferior to Repevax.",
            "startOffset": 16368
        },
        {
            "endOffset": 16513,
            "sentence": "Both vaccines were co-administered with mumps-measles-rubella vaccine.",
            "startOffset": 16443
        },
        {
            "endOffset": 16589,
            "sentence": "Both vaccines had clinically acceptable safety and reactogenicity profiles.",
            "startOffset": 16514
        }
    ],
    "bib_entries": {
        "b0005": null,
        "b0010": {
            "authors": [
                {
                    "first": "C. L.",
                    "initial": "C.L.",
                    "last": "Collins"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Salt"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "McCarthy"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Chantler"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Lane"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Hemme"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Diggle"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Buttery"
                },
                {
                    "first": "N. R.E.",
                    "initial": "N.R.E.",
                    "last": "Kitchin"
                },
                {
                    "first": "E. R.",
                    "initial": "E.R.",
                    "last": "Moxon"
                },
                {
                    "first": "A. J.",
                    "initial": "A.J.",
                    "last": "Pollard"
                }
            ],
            "doi": "10.1016/j.vaccine.2004.04.027",
            "firstpage": "4262",
            "issn": "0264410X",
            "lastpage": "4269",
            "pmid": "15474717",
            "pub_year": 2004,
            "title": "Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children",
            "volume": "22"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Tejpratap S.P.",
                    "initial": "T.S.P.",
                    "last": "Tiwari"
                },
                {
                    "first": "Melinda",
                    "initial": "M.",
                    "last": "Wharton"
                }
            ],
            "doi": "10.1016/B978-1-4557-0090-5.00024-0",
            "firstpage": "153",
            "lastpage": "166",
            "pub_year": 2012,
            "title": "Diphtheria toxoid"
        },
        "b0020": {
            "authors": [
                {
                    "first": "H. J.",
                    "initial": "H.J.",
                    "last": "Schmitt"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Schuind"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Knuf"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Beutel"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Schulte-Wissermann"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Gahr"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Schult"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Folkens"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Rauh"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Bogaerts"
                },
                {
                    "first": "H. L.",
                    "initial": "H.L.",
                    "last": "Bork"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Clemens"
                }
            ],
            "doi": "10.1016/S0022-3476(96)70152-X",
            "firstpage": "695",
            "issn": "00223476",
            "lastpage": "701",
            "pmid": "8917236",
            "pub_year": 1996,
            "title": "Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants",
            "volume": "129"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Heinz J.",
                    "initial": "H.J.",
                    "last": "Schmitt"
                },
                {
                    "first": "Carl H.Wirsing",
                    "initial": "C.H.W.",
                    "last": "Von K\u00f6nig"
                },
                {
                    "first": "Albrecht",
                    "initial": "A.",
                    "last": "Neiss"
                },
                {
                    "first": "Hugues",
                    "initial": "H.",
                    "last": "Bogaerts"
                },
                {
                    "first": "Hans L.",
                    "initial": "H.L.",
                    "last": "Bock"
                },
                {
                    "first": "Hermann",
                    "initial": "H.",
                    "last": "Schulte-Wissermann"
                },
                {
                    "first": "Manfred",
                    "initial": "M.",
                    "last": "Gahr"
                },
                {
                    "first": "Rainer",
                    "initial": "R.",
                    "last": "Schult"
                },
                {
                    "first": "Jens U.",
                    "initial": "J.U.",
                    "last": "Folkens"
                },
                {
                    "first": "Wolfgang",
                    "initial": "W.",
                    "last": "Rauh"
                },
                {
                    "first": "Ralf",
                    "initial": "R.",
                    "last": "Clemens"
                }
            ],
            "doi": "10.1001/jama.275.1.37",
            "firstpage": "37",
            "issn": "00987484",
            "lastpage": "41",
            "pmid": "8531284",
            "pub_year": 1996,
            "title": "Efficacy of acellular pertussis vaccine in early childhood after household exposure",
            "volume": "275"
        },
        "b0030": {
            "authors": [
                {
                    "first": "M. E.",
                    "initial": "M.E.",
                    "last": "Camargo"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Silveira"
                },
                {
                    "first": "J. A.",
                    "initial": "J.A.",
                    "last": "Furuta"
                },
                {
                    "first": "E. P.",
                    "initial": "E.P.",
                    "last": "Oliveira"
                },
                {
                    "first": "O. A.",
                    "initial": "O.A.",
                    "last": "Germek"
                }
            ],
            "doi": "10.1128/jcm.20.4.772-774.1984",
            "firstpage": "772",
            "issn": "00951137",
            "lastpage": "774",
            "pmid": "6386879",
            "pub_year": 1984,
            "title": "Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum",
            "volume": "20"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Moira E.",
                    "initial": "M.E.",
                    "last": "Melville-Smith"
                },
                {
                    "first": "Valerie A.",
                    "initial": "V.A.",
                    "last": "Seagroatt"
                },
                {
                    "first": "Johanna T.",
                    "initial": "J.T.",
                    "last": "Watkins"
                }
            ],
            "doi": "10.1016/S0092-1157(83)80038-9",
            "firstpage": "137",
            "issn": "00921157",
            "lastpage": "144",
            "pmid": "6345548",
            "pub_year": 1983,
            "title": "A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera",
            "volume": "11"
        },
        "b0040": {
            "authors": [
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Granstr\u00f6m"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Thor\u00e9n"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Blennow"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Tiru"
                },
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Sato"
                }
            ],
            "doi": "10.1007/BF02097184",
            "firstpage": "18",
            "issn": "07222211",
            "lastpage": "21",
            "pmid": "2883004",
            "pub_year": 1987,
            "title": "Acellular pertussis vaccine in adults: Adverse reactions and immune response",
            "volume": "6"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Sato"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Izumiya"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Sato"
                },
                {
                    "first": "J. L.",
                    "initial": "J.L.",
                    "last": "Cowell"
                },
                {
                    "first": "C. R.",
                    "initial": "C.R.",
                    "last": "Manclark"
                }
            ],
            "firstpage": "1223",
            "issn": "00199567",
            "lastpage": "1231",
            "pmid": "6262248",
            "pub_year": 1981,
            "title": "Role of antibody to leukocytosis-promoting factor hemagglutinin and to filamentous hemagglutinin in immunity to pertussis",
            "volume": "31"
        },
        "b0050": {
            "authors": [
                {
                    "first": "K. F.",
                    "initial": "K.F.",
                    "last": "Karpinski"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Hayward"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Tryphonas"
                }
            ],
            "doi": "10.1016/0022-1759(87)90289-4",
            "firstpage": "189",
            "issn": "00221759",
            "lastpage": "194",
            "pmid": "3668258",
            "pub_year": 1987,
            "title": "Statistical considerations in the quantitation of serum immunoglobulin levels using the Enzyme-Linked Immunosorbent Assay (ELISA)",
            "volume": "103"
        },
        "b0055": {
            "authors": [
                {
                    "first": "P. W.",
                    "initial": "P.W.",
                    "last": "Neumann"
                },
                {
                    "first": "J. M.",
                    "initial": "J.M.",
                    "last": "Weber"
                },
                {
                    "first": "A. G.",
                    "initial": "A.G.",
                    "last": "Jessamine"
                },
                {
                    "first": "M. V.",
                    "initial": "M.V.",
                    "last": "O'Shaughnessy"
                }
            ],
            "firstpage": "296",
            "issn": "00951137",
            "lastpage": "298",
            "pmid": "3897272",
            "pub_year": 1985,
            "title": "Comparison of measles antihemolysin test, enzyme-linked immunosorbent assay, and hemagglutination inhibition test with neutralization test for determination of immune status",
            "volume": "22"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Pauli O.",
                    "initial": "P.O.",
                    "last": "Leinikki"
                },
                {
                    "first": "Isabel",
                    "initial": "I.",
                    "last": "Shekarchi"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Tzan"
                },
                {
                    "first": "David L.",
                    "initial": "D.L.",
                    "last": "Madden"
                },
                {
                    "first": "John L.",
                    "initial": "J.L.",
                    "last": "Sever"
                }
            ],
            "doi": "10.3181/00379727-160-40451",
            "firstpage": "363",
            "issn": "00379727",
            "lastpage": "367",
            "pmid": "372952",
            "pub_year": 1979,
            "title": "Evaluation of Enzyme-Linked Immunosorbent Assay (ELISA) for Mumps Virus Antibodies",
            "volume": "160"
        },
        "b0065": null,
        "b0070": {
            "authors": [
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "firstpage": "1",
            "issn": "05123054",
            "lastpage": "262",
            "pmid": "26714369",
            "pub_year": 2015,
            "title": "WHO Expert Committee on Biological Standardization. Sixty-fifth report"
        },
        "b0075": {
            "authors": [
                {
                    "first": "A. Dale",
                    "initial": "A.D.",
                    "last": "Horne"
                },
                {
                    "first": "Peter A.",
                    "initial": "P.A.",
                    "last": "Lachenbruch"
                },
                {
                    "first": "Pamela R.",
                    "initial": "P.R.",
                    "last": "Getson"
                },
                {
                    "first": "Henry S.",
                    "initial": "H.S.",
                    "last": "Hsu"
                }
            ],
            "doi": "10.1086/322566",
            "firstpage": "S306",
            "issn": "10584838",
            "lastpage": "S311",
            "pmid": "11709764",
            "pub_year": 2001,
            "title": "Analysis of studies to evaluate immune response to combination vaccines",
            "volume": "33"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Michael E.",
                    "initial": "M.E.",
                    "last": "Pichichero"
                },
                {
                    "first": "Mark M.",
                    "initial": "M.M.",
                    "last": "Blatter"
                },
                {
                    "first": "William A.",
                    "initial": "W.A.",
                    "last": "Kennedy"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Hedrick"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Descamps"
                },
                {
                    "first": "Leonard R.",
                    "initial": "L.R.",
                    "last": "Friedland"
                }
            ],
            "doi": "10.1542/peds.2005-1759",
            "firstpage": "1084",
            "issn": "00314005",
            "lastpage": "1093",
            "pmid": "16585302",
            "pub_year": 2006,
            "title": "Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents",
            "volume": "117"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Nicholas",
                    "initial": "N.",
                    "last": "Kitchin"
                },
                {
                    "first": "Joanna",
                    "initial": "J.",
                    "last": "Southern"
                },
                {
                    "first": "Rhonwen",
                    "initial": "R.",
                    "last": "Morris"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Fiquet"
                },
                {
                    "first": "Florence",
                    "initial": "F.",
                    "last": "Boisnard"
                },
                {
                    "first": "St\u00e9phane",
                    "initial": "S.",
                    "last": "Thomas"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.06.049",
            "firstpage": "5096",
            "issn": "0264410X",
            "lastpage": "5102",
            "pmid": "19573637",
            "pub_year": 2009,
            "title": "Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine",
            "volume": "27"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Brigitte",
                    "initial": "B.",
                    "last": "Cheuvart"
                },
                {
                    "first": "Margaret",
                    "initial": "M.",
                    "last": "Burgess"
                },
                {
                    "first": "Fred",
                    "initial": "F.",
                    "last": "Zepp"
                },
                {
                    "first": "Jussi",
                    "initial": "J.",
                    "last": "Mertsola"
                },
                {
                    "first": "Joanne",
                    "initial": "J.",
                    "last": "Wolter"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1016/j.vaccine.2004.06.012",
            "firstpage": "336",
            "issn": "0264410X",
            "lastpage": "342",
            "pmid": "15530678",
            "pub_year": 2004,
            "title": "Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model",
            "volume": "23"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Nicola P.",
                    "initial": "N.P.",
                    "last": "Klein"
                },
                {
                    "first": "Joan",
                    "initial": "J.",
                    "last": "Bartlett"
                },
                {
                    "first": "Bruce",
                    "initial": "B.",
                    "last": "Fireman"
                },
                {
                    "first": "Laurie",
                    "initial": "L.",
                    "last": "Aukes"
                },
                {
                    "first": "Philip O.",
                    "initial": "P.O.",
                    "last": "Buck"
                },
                {
                    "first": "Girishanthy",
                    "initial": "G.",
                    "last": "Krishnarajah"
                },
                {
                    "first": "Roger",
                    "initial": "R.",
                    "last": "Baxter"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.05.008",
            "firstpage": "3395",
            "issn": "0264410X",
            "lastpage": "3400",
            "pmid": "28506516",
            "pub_year": 2017,
            "title": "Waning protection following 5 doses of a 3-component diphtheria, tetanus, and acellular pertussis vaccine",
            "volume": "35"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Keith R.",
                    "initial": "K.R.",
                    "last": "Powell"
                },
                {
                    "first": "Robert S.",
                    "initial": "R.S.",
                    "last": "Baltimore"
                },
                {
                    "first": "Henry H.",
                    "initial": "H.H.",
                    "last": "Bernstein"
                },
                {
                    "first": "Joseph A.",
                    "initial": "J.A.",
                    "last": "Bocchini"
                },
                {
                    "first": "John S.",
                    "initial": "J.S.",
                    "last": "Bradley"
                },
                {
                    "first": "Michael T.",
                    "initial": "M.T.",
                    "last": "Brady"
                },
                {
                    "first": "Penelope H.",
                    "initial": "P.H.",
                    "last": "Dennehy"
                },
                {
                    "first": "Robert W.",
                    "initial": "R.W.",
                    "last": "Frenck"
                },
                {
                    "first": "David W.",
                    "initial": "D.W.",
                    "last": "Kimberlin"
                },
                {
                    "first": "Sarah S.",
                    "initial": "S.S.",
                    "last": "Long"
                },
                {
                    "first": "Julia A.",
                    "initial": "J.A.",
                    "last": "McMillan"
                },
                {
                    "first": "Lorry G.",
                    "initial": "L.G.",
                    "last": "Rubin"
                },
                {
                    "first": "Richard D.",
                    "initial": "R.D.",
                    "last": "Clover"
                },
                {
                    "first": "Stephen L.",
                    "initial": "S.L.",
                    "last": "Cochi"
                },
                {
                    "first": "Joanne",
                    "initial": "J.",
                    "last": "Embree"
                },
                {
                    "first": "Marc A.",
                    "initial": "M.A.",
                    "last": "Fischer"
                },
                {
                    "first": "Mamodikoe",
                    "initial": "M.",
                    "last": "Makhene"
                },
                {
                    "first": "Douglas R.",
                    "initial": "D.R.",
                    "last": "Pratt"
                },
                {
                    "first": "Benjamin",
                    "initial": "B.",
                    "last": "Schwartz"
                },
                {
                    "first": "Jeffrey R.",
                    "initial": "J.R.",
                    "last": "Starke"
                },
                {
                    "first": "Jack",
                    "initial": "J.",
                    "last": "Swanson"
                },
                {
                    "first": "Larry K.",
                    "initial": "L.K.",
                    "last": "Pickering"
                },
                {
                    "first": "Edgar O.",
                    "initial": "E.O.",
                    "last": "Ledbetter"
                },
                {
                    "first": "Alison",
                    "initial": "A.",
                    "last": "Siwek"
                }
            ],
            "doi": "10.1542/peds.2005-3038",
            "firstpage": "965",
            "issn": "00314005",
            "lastpage": "978",
            "pmid": "16382131",
            "pub_year": 2006,
            "title": "Prevention of pertussis among adolescents: Recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine",
            "volume": "117"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Gayatri",
                    "initial": "G.",
                    "last": "Amirthalingam"
                },
                {
                    "first": "Nick",
                    "initial": "N.",
                    "last": "Andrews"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Campbell"
                },
                {
                    "first": "Sonia",
                    "initial": "S.",
                    "last": "Ribeiro"
                },
                {
                    "first": "Edna",
                    "initial": "E.",
                    "last": "Kara"
                },
                {
                    "first": "Katherine",
                    "initial": "K.",
                    "last": "Donegan"
                },
                {
                    "first": "Norman K.",
                    "initial": "N.K.",
                    "last": "Fry"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Miller"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Ramsay"
                }
            ],
            "doi": "10.1016/S0140-6736(14)60686-3",
            "firstpage": "1521",
            "issn": "01406736",
            "lastpage": "1528",
            "pmid": "25037990",
            "pub_year": 2014,
            "title": "Effectiveness of maternal pertussis vaccination in England: An observational study",
            "volume": "384"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Shamez N.",
                    "initial": "S.N.",
                    "last": "Ladhani"
                },
                {
                    "first": "Nick J.",
                    "initial": "N.J.",
                    "last": "Andrews"
                },
                {
                    "first": "Jo",
                    "initial": "J.",
                    "last": "Southern"
                },
                {
                    "first": "Christine E.",
                    "initial": "C.E.",
                    "last": "Jones"
                },
                {
                    "first": "Gayatri",
                    "initial": "G.",
                    "last": "Amirthalingam"
                },
                {
                    "first": "Pauline A.",
                    "initial": "P.A.",
                    "last": "Waight"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "England"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Matheson"
                },
                {
                    "first": "Xilian",
                    "initial": "X.",
                    "last": "Bai"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Findlow"
                },
                {
                    "first": "Polly",
                    "initial": "P.",
                    "last": "Burbidge"
                },
                {
                    "first": "Vasili",
                    "initial": "V.",
                    "last": "Thalasselis"
                },
                {
                    "first": "Bassam",
                    "initial": "B.",
                    "last": "Hallis"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Goldblatt"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Paul T.",
                    "initial": "P.T.",
                    "last": "Heath"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1093/cid/civ695",
            "firstpage": "1637",
            "issn": "10584838",
            "lastpage": "1644",
            "pmid": "26374816",
            "pub_year": 2015,
            "title": "Antibody responses after primary immunization in infants born to women receiving a Pertussis-containing vaccine during pregnancy: Single arm observational study with a historical comparator",
            "volume": "61"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Merryn",
                    "initial": "M.",
                    "last": "Voysey"
                },
                {
                    "first": "Dominic F.",
                    "initial": "D.F.",
                    "last": "Kelly"
                },
                {
                    "first": "Thomas R.",
                    "initial": "T.R.",
                    "last": "Fanshawe"
                },
                {
                    "first": "Manish",
                    "initial": "M.",
                    "last": "Sadarangani"
                },
                {
                    "first": "Katherine L.",
                    "initial": "K.L.",
                    "last": "O'Brien"
                },
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Perera"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Pollard"
                }
            ],
            "doi": "10.1001/jamapediatrics.2017.0638",
            "firstpage": "637",
            "issn": "21686203",
            "lastpage": "646",
            "pmid": "28505244",
            "pub_year": 2017,
            "title": "The influence of maternally derived antibody and infant age at vaccination on infant vaccine responses: An individual participant meta-analysis",
            "volume": "171"
        }
    },
    "body_text": [
        {
            "endOffset": 33817,
            "parents": [],
            "secId": "s0070",
            "sentence": "This study compares the immunogenicity and AEs of two alternative dTap-IPV vaccines for use as a pre-school booster in the UK vaccine schedule.",
            "startOffset": 33674,
            "title": "Discussion"
        },
        {
            "endOffset": 36240,
            "parents": [],
            "refoffsets": {
                "b0095": {
                    "endOffset": 36165,
                    "startOffset": 36161
                },
                "b0100": {
                    "endOffset": 36239,
                    "startOffset": 36235
                }
            },
            "secId": "s0070",
            "sentence": "However even with adequate pertussis vaccine responses, data from the US have shown rapid waning of clinical protection (27% per year after the fifth dose of pertussis vaccine) [19] leading the US to introduce an adolescent booster dose for pertussis [20].",
            "startOffset": 35984,
            "title": "Discussion"
        },
        {
            "endOffset": 32241,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Prior to boosting, evidence of antibodies persistence for the MMR vaccine (Table 4) was observed for at least 89.7% of children meeting the immunological criteria for measles, mumps or rubella in each group.",
            "startOffset": 32034,
            "title": "Immunogenicity results"
        },
        {
            "endOffset": 33663,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "No study participants withdrew from the study due to an AE or SAE.",
            "startOffset": 33597,
            "title": "Safety results"
        },
        {
            "endOffset": 33113,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "During the 31-day (Days 0\u201330) post vaccination unsolicited reporting period, 88/255 (34.5%; dTap-IPVB) and 36/130 (27.7%; dTap-IPVR) (p = 0.22) of participants reported at least one AE of which 4.7% and 4.6% (p = 1.0) respectively were considered to be severe.",
            "startOffset": 32853,
            "title": "Safety results"
        },
        {
            "endOffset": 22693,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The immune response to pertussis antigens induced by dTap-IPVB when compared to historical data relating to DTaP vaccine (Infanrix vaccine, GSK) when administered to infants.",
            "startOffset": 22519,
            "title": "Participants"
        },
        {
            "endOffset": 20123,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 20122,
                    "startOffset": 20119
                }
            },
            "secId": "s0005",
            "sentence": "At this age low dose diphtheria vaccines have been shown to induce adequate immune responses but with the advantage of lower rates of local side effects [3].",
            "startOffset": 19966,
            "title": "Introduction"
        },
        {
            "endOffset": 24568,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Solicited local and general symptoms occurring within four days following vaccination were recorded in diary cards as were other (unsolicited) adverse events (AEs) occurring within 30 days of vaccination.",
            "startOffset": 24364,
            "title": "Study procedures"
        },
        {
            "endOffset": 25674,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0030": {
                    "endOffset": 25673,
                    "startOffset": 25668
                },
                "b0035": {
                    "endOffset": 25673,
                    "startOffset": 25668
                }
            },
            "secId": "s0030",
            "sentence": "For both anti-diphtheria and tetanus thresholds for correlates of clinical protection were defined as 0.1 international units per millilitre (IU/ml), three times the lower quantification limit of the assays as previously demonstrated [6,7].",
            "startOffset": 25434,
            "title": "Laboratory assays"
        },
        {
            "endOffset": 36760,
            "parents": [],
            "secId": "s0070",
            "sentence": "This meant that for AE recording the parents were not blinded to the study arm \u2013 despite this there were no significant differences between AE outcomes.",
            "startOffset": 36608,
            "title": "Discussion"
        },
        {
            "endOffset": 35614,
            "parents": [],
            "secId": "s0070",
            "sentence": "This primary analysis showed non-inferiority.",
            "startOffset": 35569,
            "title": "Discussion"
        },
        {
            "endOffset": 21214,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Ethical approval was obtained from the South West 2 Research Ethics Committee (NHS REC Ref: 10/H0206/43).",
            "startOffset": 21109,
            "title": "Study design and setting"
        },
        {
            "endOffset": 22872,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Both study vaccines contained diphtheria (low amounts) and tetanus toxoids, pertussis antigens (low amounts) and three polio strains (vaccine composition is presented in Table 1).",
            "startOffset": 22693,
            "title": "Participants"
        },
        {
            "endOffset": 24678,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Information on serious adverse events (SAEs) occurring at any time-point during the study was also collected.",
            "startOffset": 24569,
            "title": "Study procedures"
        },
        {
            "endOffset": 37949,
            "parents": [],
            "secId": "s0080",
            "sentence": "This study and related publication were sponsored by GlaxoSmithKline Biologicals SA.",
            "startOffset": 37865,
            "title": "Funding"
        },
        {
            "endOffset": 29143,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Statistics"
                }
            ],
            "secId": "s0045",
            "sentence": "Additionally, p values for the difference in proportion of participants reporting the solicited symptom, and solicited and unsolicited symptoms combined, were computed post hoc using the continuity adjusted chi-square method.",
            "startOffset": 28918,
            "title": "Safety"
        },
        {
            "endOffset": 37120,
            "parents": [],
            "refoffsets": {
                "b0105": {
                    "endOffset": 37119,
                    "startOffset": 37115
                }
            },
            "secId": "s0070",
            "sentence": "This has been highly successful with significant reduction in the number of cases [21].",
            "startOffset": 37033,
            "title": "Discussion"
        },
        {
            "endOffset": 19526,
            "parents": [],
            "secId": "s0005",
            "sentence": "Most countries give two or three doses in the first six months (m) followed by one at 12\u201318 m (termed 2 + 1/3 + 1 schedules) with a further booster before starting school.",
            "startOffset": 19355,
            "title": "Introduction"
        },
        {
            "endOffset": 31419,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "For the secondary analyses the pre booster titres (Table 4) showed that prior to boosting for all antigens a high proportion of children in both groups had antibody levels below the defined seroprotection/seropositivity thresholds; with 16.7\u201334.5% for diphtheria and tetanus and 30.4\u201340.6% for polio.",
            "startOffset": 31119,
            "title": "Immunogenicity results"
        },
        {
            "endOffset": 24363,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Vaccines were given intramuscularly dTap-IPV into the left deltoid, MMR into right deltoid, using 25 mm 23 G needles, respectively.",
            "startOffset": 24232,
            "title": "Study procedures"
        },
        {
            "endOffset": 27311,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Statistics"
                }
            ],
            "refoffsets": {
                "b0020": {
                    "endOffset": 27232,
                    "startOffset": 27227
                },
                "b0025": {
                    "endOffset": 27232,
                    "startOffset": 27227
                }
            },
            "secId": "s0040",
            "sentence": "For diphtheria and tetanus responses \u2013 the upper 95% confidence interval (CI) limit of the (dTap-IPVR group minus dTap-IPVB group) difference between the percentage of participants in the two groups with post-vaccine antibody concentrations above the pre-defined protective threshold was to be less than 10%; for poliovirus types 1, 2 and 3 \u2013 the upper 95% CI limit of the ratio of geometric mean titres (GMTs) (dTap-IPVR group divided by dTap-IPVB group) was to be less than or equal to two and for pertussis antigens \u2013 the upper 95% CI limit of the ratio of geometric mean concentrations (GMCs) (historic DTaP data [4,5] divided by dTap-IPVB group in this study) was to be less than or equal to 1.5.",
            "startOffset": 26610,
            "title": "Analysis of immunogenicity"
        },
        {
            "endOffset": 31532,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "For pertussis 29.4\u201381.9% of participants had IgG titres below the pre-determined optimal serological thresholds.",
            "startOffset": 31420,
            "title": "Immunogenicity results"
        },
        {
            "endOffset": 24176,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "After randomisation, the study was open label with both investigator and child\u2019s parents aware of their allocation.",
            "startOffset": 24061,
            "title": "Study procedures"
        },
        {
            "endOffset": 30753,
            "parents": [],
            "secId": "s0055",
            "sentence": "As per protocol, an additional total vaccinated cohort immunogenicity analysis was performed but found no significant difference in primary or secondary outcomes \u2013 results are provided as an online appendix (Supplementary Tables 3\u20135).",
            "startOffset": 30519,
            "title": "Results"
        },
        {
            "endOffset": 34494,
            "parents": [],
            "secId": "s0070",
            "sentence": "In this study which followed the UK infant schedule in use at that time, we found that by the age of three and a half years, almost a third of children had antibody levels that had waned below desired levels for at least one vaccine component (Table 4) \u2013 reinforcing the requirement for a pre-school booster.",
            "startOffset": 34186,
            "title": "Discussion"
        },
        {
            "endOffset": 32853,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Severe (grade 3) symptoms were reported by a maximum of 11.0% (redness in the dTap-IPVB group) and 18.4% (redness in the dTap-IPVR group) (p = 0.08) of participants (Table 5).",
            "startOffset": 32678,
            "title": "Safety results"
        },
        {
            "endOffset": 20717,
            "parents": [],
            "secId": "s0005",
            "sentence": "Thus we aimed to demonstrate that the immunogenicity of dTap-IPVB is not inferior to that of dTap-IPVR (Repevax, Sanofi-Pasteur), the vaccine in routine use at the time in the UK and which is approved for use in persons from three years of age upwards.",
            "startOffset": 20465,
            "title": "Introduction"
        },
        {
            "endOffset": 21337,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The trial was registered with the European Clinical Trials Database (2009-012202-39) and ClinicalTrials.gov (NCT01245049).",
            "startOffset": 21215,
            "title": "Study design and setting"
        },
        {
            "endOffset": 24231,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "A blood sample (2.5 mls) was drawn before vaccination.",
            "startOffset": 24177,
            "title": "Study procedures"
        },
        {
            "endOffset": 30518,
            "parents": [],
            "secId": "s0055",
            "sentence": "The ATP immunogenicity cohort comprised 76.5%/73.8% (dTap-IPVB/dTap-IPVR, respectively) of the total vaccinated cohort mainly due to missing serological data through difficulties in obtaining blood samples.",
            "startOffset": 30312,
            "title": "Results"
        },
        {
            "endOffset": 35295,
            "parents": [],
            "secId": "s0070",
            "sentence": "With no agreed immunological correlate of protection against pertussis, it was not appropriate to simply compare the antibody response between the two study vaccines because dTap-IPVR contains two additional pertussis antigens.",
            "startOffset": 35068,
            "title": "Discussion"
        },
        {
            "endOffset": 22031,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Full exclusion criteria are listed in online supplement (Supplementary Table 1).",
            "startOffset": 21951,
            "title": "Participants"
        },
        {
            "endOffset": 21108,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "We conducted an open-label, randomised, multicentre trial in five paediatric research centres in the UK (Bristol, Exeter, Oxford, Southampton and Taunton) and seven general practices.",
            "startOffset": 20925,
            "title": "Study design and setting"
        },
        {
            "endOffset": 34668,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 34667,
                    "startOffset": 34663
                }
            },
            "secId": "s0070",
            "sentence": "This is in line with a previous study showing serological evidence of protection from UK primary course DTaP had substantially waned by the age of three to -four years [17].",
            "startOffset": 34495,
            "title": "Discussion"
        },
        {
            "endOffset": 35068,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 35067,
                    "startOffset": 35063
                }
            },
            "secId": "s0070",
            "sentence": "Due to the long half\u2013life of these antibodies, this degree of boosting above the protective threshold has been shown to remain clinically effective for ten years, based on a mathematical model [18].",
            "startOffset": 34870,
            "title": "Discussion"
        },
        {
            "endOffset": 37858,
            "parents": [],
            "secId": "s0075",
            "sentence": "Repevax is a trade mark of Sanofi-Pasteur.",
            "startOffset": 37816,
            "title": "Trademark statement"
        },
        {
            "endOffset": 20281,
            "parents": [],
            "secId": "s0005",
            "sentence": "dTap-IPV (dTap-IPVB; Boostrix-IPV, GSK) is already used as a pre-school booster in many countries around the world but is licensed only from the age of four.",
            "startOffset": 20124,
            "title": "Introduction"
        },
        {
            "endOffset": 37309,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 37242,
                    "startOffset": 37235
                },
                "b0115": {
                    "endOffset": 37242,
                    "startOffset": 37235
                }
            },
            "secId": "s0070",
            "sentence": "However there is some evidence that increased maternal titres may adversely affect early infant vaccine responses [22,23], increasing the importance of an effective the pre-school booster.",
            "startOffset": 37121,
            "title": "Discussion"
        },
        {
            "endOffset": 32609,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In the four day post vaccination period, 216/255 (84.7%; dTap-IPVB) and 108/130 (83.1%; dTap-IPVR) (p = 0.79) of participants reported at least one solicited symptom or unsolicited AE.",
            "startOffset": 32425,
            "title": "Safety results"
        },
        {
            "endOffset": 29797,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Statistics"
                }
            ],
            "secId": "s0050",
            "sentence": "Assuming a dropout rate of 10%, a total of 384 participants (256 participants in dTap-IPVB group and 128 in dTap-IPVR group) was chosen to ensure that a sufficient number of evaluable participants was available for inclusion in the per protocol cohort for analysis of immunogenicity.",
            "startOffset": 29514,
            "title": "Sample size"
        },
        {
            "endOffset": 23585,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "At the first, written informed consent was obtained from the parent/legal guardian.",
            "startOffset": 23502,
            "title": "Study procedures"
        },
        {
            "endOffset": 29931,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Statistics"
                }
            ],
            "secId": "s0050",
            "sentence": "Statistical analysis was done by GSK with independent statistical verification carried out by KJC statistics (www.kjcstatistics.com).",
            "startOffset": 29798,
            "title": "Sample size"
        },
        {
            "endOffset": 23501,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "After initial contact and eligibility checking, the study comprised two visits.",
            "startOffset": 23422,
            "title": "Study procedures"
        },
        {
            "endOffset": 19776,
            "parents": [],
            "secId": "s0005",
            "sentence": "However the UK schedule just has three infant doses with no DTaP-IPV booster at 12\u201318 m; at this visit children already receive four injections (Haemophilus influenzae type B, pneumococcal conjugate, mumps-measles-rubella [MMR] and meningococcal B).",
            "startOffset": 19527,
            "title": "Introduction"
        },
        {
            "endOffset": 29983,
            "parents": [],
            "secId": "s0055",
            "sentence": "The study ran from April 2011 to April 2012.",
            "startOffset": 29939,
            "title": "Results"
        },
        {
            "endOffset": 32677,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "For both vaccines redness and pain were the most commonly reported.",
            "startOffset": 32610,
            "title": "Safety results"
        },
        {
            "endOffset": 36903,
            "parents": [],
            "secId": "s0070",
            "sentence": "Since the study the UK infant vaccine schedule has changed with the introduction of the rotavirus and meningococcal B immunisation programmes.",
            "startOffset": 36761,
            "title": "Discussion"
        },
        {
            "endOffset": 37587,
            "parents": [],
            "secId": "s0070",
            "sentence": "In conclusion, we found dTap-IPVB to be non-inferior to dTap-IPVR with all children making an equivalent immune response after boosting indicative of protection being afforded at the same level as demonstrated now in the population as monitored by national surveillance systems.",
            "startOffset": 37309,
            "title": "Discussion"
        },
        {
            "endOffset": 28917,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Statistics"
                }
            ],
            "secId": "s0045",
            "sentence": "The intensity of solicited symptoms was graded as mild, moderate or severe (defined in Supplementary Table 2) and assessment of causality by vaccination was assessed by investigators.",
            "startOffset": 28734,
            "title": "Safety"
        },
        {
            "endOffset": 34186,
            "parents": [],
            "secId": "s0070",
            "sentence": "There were no significant differences in solicited or unsolicited local reactions between the two vaccines, with mild redness and pain reported in 49.8\u201358.4% of cases.",
            "startOffset": 34019,
            "title": "Discussion"
        },
        {
            "endOffset": 24993,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "All assays were performed at the laboratories of GSK Biologicals (Rixensart, Belgium) with laboratory staff blinded to the participant group.",
            "startOffset": 24852,
            "title": "Laboratory assays"
        },
        {
            "endOffset": 24832,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The second and final study visit was 30 days (range: 21\u201348 days) after the first visit and comprised a second blood sample and collection of diary cards.",
            "startOffset": 24679,
            "title": "Study procedures"
        },
        {
            "endOffset": 22970,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "However dTap-IPVB contained three of the five pertussis antigens in dTap-IPVR at different doses.",
            "startOffset": 22873,
            "title": "Participants"
        },
        {
            "endOffset": 28276,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Statistics"
                }
            ],
            "secId": "s0040",
            "sentence": "If, in any vaccine group, the percentage of vaccinated participants with serological results excluded from this ATP cohort was 5% or more, a second analysis of the total vaccinated cohort was to be performed to complement the ATP analysis.",
            "startOffset": 28037,
            "title": "Analysis of immunogenicity"
        },
        {
            "endOffset": 33596,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "This was felt not to be causally related to vaccination by the investigator.",
            "startOffset": 33520,
            "title": "Safety results"
        },
        {
            "endOffset": 36440,
            "parents": [],
            "secId": "s0070",
            "sentence": "Further investigations would need to be done to determine if the additional pertussis antigen contained in dTap-IPVR resulted in any significant difference in the rate of waning between the vaccines.",
            "startOffset": 36241,
            "title": "Discussion"
        },
        {
            "endOffset": 30311,
            "parents": [],
            "secId": "s0055",
            "sentence": "There were no significant differences in baseline characteristics in the ATP immunogenicity cohort: in both groups mean age at vaccination was 3.1 years with an equal proportion of genders and similar heritage (Table 2).",
            "startOffset": 30091,
            "title": "Results"
        },
        {
            "endOffset": 28036,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Statistics"
                }
            ],
            "secId": "s0040",
            "sentence": "The primary analysis was based on the cohort of participants who completed the study according to protocol (ATP) for analysis of immunogenicity.",
            "startOffset": 27892,
            "title": "Analysis of immunogenicity"
        },
        {
            "endOffset": 25433,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Specific IgG antibodies to measles, mumps and rubella were measured using commercially available ELISAs following the manufacturers\u2019 instructions (Dade Behring, Germany).",
            "startOffset": 25263,
            "title": "Laboratory assays"
        },
        {
            "endOffset": 23242,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0020": {
                    "endOffset": 23141,
                    "startOffset": 23138
                },
                "b0025": {
                    "endOffset": 23158,
                    "startOffset": 23155
                }
            },
            "secId": "s0020",
            "sentence": "With no available immunological correlate of protection for pertussis, it was felt that the most clinically relevant comparator would be the historical immunogenicity [4] and efficacy [5] data originally supporting the licensure of this combination of pertussis antigens.",
            "startOffset": 22971,
            "title": "Participants"
        },
        {
            "endOffset": 36607,
            "parents": [],
            "secId": "s0070",
            "sentence": "The limitation of this study is that whilst randomised, because of the difference in the visual aspects of the study vaccines, the study was designed to be open label.",
            "startOffset": 36440,
            "title": "Discussion"
        },
        {
            "endOffset": 21757,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Eligible participants were healthy children between three and less than five years of age who had had their previous vaccines on time as per national immunization program in the UK (three diphtheria, tetanus, pertussis and polio doses primary schedule completed before six months of age and first MMR vaccine before two years of age) but had not already received their routine pre-school dTap-IPV booster.",
            "startOffset": 21352,
            "title": "Participants"
        },
        {
            "endOffset": 37032,
            "parents": [],
            "secId": "s0070",
            "sentence": "In response to rising rates of neonatal pertussis, in 2012 the UK introduced maternal dTap vaccination at 28\u201332 weeks gestation.",
            "startOffset": 36904,
            "title": "Discussion"
        },
        {
            "endOffset": 29247,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Statistics"
                }
            ],
            "secId": "s0045",
            "sentence": "However, the results should be interpreted with caution since there was no adjustment for multiplicity.",
            "startOffset": 29144,
            "title": "Safety"
        },
        {
            "endOffset": 26501,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0070": {
                    "endOffset": 26500,
                    "startOffset": 26496
                }
            },
            "secId": "s0030",
            "sentence": "Polio antibody titres greater than or equal to 1:8 dilution were considered seropositive and protective [14].",
            "startOffset": 26392,
            "title": "Laboratory assays"
        },
        {
            "endOffset": 37716,
            "parents": [],
            "secId": "s0070",
            "sentence": "There were minor differences between vaccines for individual antigens but these are unlikely to be of any clinical significance.",
            "startOffset": 37588,
            "title": "Discussion"
        },
        {
            "endOffset": 21950,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Children were excluded from participating if they had a known allergy to the vaccine components, known immunodeficiency, chronic use of steroids or were concurrently in another clinical trial.",
            "startOffset": 21758,
            "title": "Participants"
        },
        {
            "endOffset": 23403,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The study design and endpoints were decided in liaison with the European Medicines Agency (EMA) to meet requirements for Paediatric Investigation Plan approval.",
            "startOffset": 23243,
            "title": "Participants"
        },
        {
            "endOffset": 26134,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Seroconversion was defined as seropositivity in the relevant assay in participants seronegative before vaccination.",
            "startOffset": 26019,
            "title": "Laboratory assays"
        },
        {
            "endOffset": 32408,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "One month after the MMR booster dose all children had antibody titres above the defined immunological criteria with no significant differences in GMTs between groups.",
            "startOffset": 32242,
            "title": "Immunogenicity results"
        },
        {
            "endOffset": 19354,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 19353,
                    "startOffset": 19350
                }
            },
            "secId": "s0005",
            "sentence": "The timing of primary and booster doses of diphtheria (d), tetanus (T), acellular pertussis (ap) and inactivated poliovirus (IPV) varies widely across Europe [1].",
            "startOffset": 19192,
            "title": "Introduction"
        },
        {
            "endOffset": 22385,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Co-primary objectives were to demonstrate, one month after vaccination, non-inferiority of",
            "startOffset": 22295,
            "title": "Participants"
        },
        {
            "endOffset": 22154,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Families were recruited either using postal mailings through local Child Health Databases or from their general practices.",
            "startOffset": 22032,
            "title": "Participants"
        },
        {
            "endOffset": 33370,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Diarrhoea and vomiting, reported for 9/255 (3.5%) participants were the most frequently reported unsolicited AE in the dTap-IPVB group while rash, reported for 6/130 (4.6%) participants was the most frequently reported unsolicited AE in the dTap-IPVR group.",
            "startOffset": 33113,
            "title": "Safety results"
        },
        {
            "endOffset": 22295,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Vaccination was postponed for any intercurrent febrile illness with axillary temperature \u226537.5 \u00b0C or other moderate to severe acute illness.",
            "startOffset": 22155,
            "title": "Participants"
        },
        {
            "endOffset": 19965,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 19889,
                    "startOffset": 19886
                }
            },
            "secId": "s0005",
            "sentence": "By three to five years of age the protection gained from primary vaccinations in infancy is starting to wane [2] so the pre-school booster is given between three and a half and four years.",
            "startOffset": 19777,
            "title": "Introduction"
        },
        {
            "endOffset": 25262,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Antibodies against diphtheria toxoid (anti-diphtheria), tetanus toxoid (anti-tetanus) and pertussis components (pertussis toxoid [PT], filamentous haemagglutinin [FHA] and pertactin [PRN]) were measured by enzyme-linked immunosorbent assays (ELISA) developed in-house.",
            "startOffset": 24994,
            "title": "Laboratory assays"
        },
        {
            "endOffset": 35701,
            "parents": [],
            "secId": "s0070",
            "sentence": "In a secondary analysis we compared the GMCs for the antigens common to both vaccines.",
            "startOffset": 35615,
            "title": "Discussion"
        },
        {
            "endOffset": 32034,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Comparing antibody GMC/GMT between the two study vaccines at one month post dTap-IPV vaccination (Table 4), marginally higher point estimates for diphtheria, tetanus, Polio3 and PRN after dTap-IPVR vaccination, and marginally higher point estimates for the Polio1, Polio2, PT and FHA after dTap-IPVB vaccination were observed.",
            "startOffset": 31708,
            "title": "Immunogenicity results"
        },
        {
            "endOffset": 24060,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Children were then randomised using GSK\u2019s central Internet Randomisation system (SBIR) (using a block size of six and a minimisation procedure accounting for centre) and allocated to receive either dTap-IPVB (lots AC39B034B, AC39B026A, AC39B032A1) or dTap-IPVR (lots DEXTA397AZ, DEXTA419AZ) in a 2:1 ratio as their pre-school dTap-IPV booster with both groups also receiving a dose of MMR booster (Priorix, GSK, Lots AMJRB892AZ, AMJRC160AZ, AD01B679C, AD01B801A, AD01B733B).",
            "startOffset": 23586,
            "title": "Study procedures"
        },
        {
            "endOffset": 35983,
            "parents": [],
            "secId": "s0070",
            "sentence": "Clearly both vaccines used as boosters can provide a serological response.",
            "startOffset": 35909,
            "title": "Discussion"
        },
        {
            "endOffset": 29513,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Statistics"
                }
            ],
            "secId": "s0050",
            "sentence": "It was calculated that 230 participants in the dTap-IPVB group and 115 in the dTap-IPVR group (a total of 345) would provide at least 90% overall power to reach conclusions on all the co-primary objectives simultaneously (with Bonferroni adjustment).",
            "startOffset": 29263,
            "title": "Sample size"
        },
        {
            "endOffset": 37815,
            "parents": [],
            "secId": "s0075",
            "sentence": "Boostrix-IPV, Infanrix and Priorix are trademarks of the GSK group of companies.",
            "startOffset": 37735,
            "title": "Trademark statement"
        },
        {
            "endOffset": 34018,
            "parents": [],
            "secId": "s0070",
            "sentence": "According to the primary outcomes, the study vaccine response was non-inferior to its comparator at one month post-vaccination \u2013 both vaccines boosting serological responses above accepted thresholds.",
            "startOffset": 33818,
            "title": "Discussion"
        },
        {
            "endOffset": 22516,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The immune responses to diphtheria, tetanus and polio antigens induced by dTap-IPVB when compared to those induced by dTap-IPVR.",
            "startOffset": 22388,
            "title": "Participants"
        },
        {
            "endOffset": 26018,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0040": {
                    "endOffset": 25761,
                    "startOffset": 25755
                },
                "b0045": {
                    "endOffset": 25761,
                    "startOffset": 25755
                },
                "b0050": {
                    "endOffset": 25761,
                    "startOffset": 25755
                },
                "b0055": {
                    "endOffset": 25775,
                    "startOffset": 25771
                },
                "b0060": {
                    "endOffset": 25787,
                    "startOffset": 25783
                }
            },
            "secId": "s0030",
            "sentence": "With no established serological correlates of protection for pertussis antigens [8\u201310], measles [11], mumps [12] or rubella, the thresholds for serological responses (positive: greater than or equal) were arbitrarily defined as the lower limits of the assays: 5 El.U/ml (all pertussis antigens), 150 mIU/ml, 231 U/ml and 4 IU/ml, respectively.",
            "startOffset": 25675,
            "title": "Laboratory assays"
        },
        {
            "endOffset": 26391,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0065": {
                    "endOffset": 26309,
                    "startOffset": 26305
                }
            },
            "secId": "s0030",
            "sentence": "Antibody titres against poliovirus types 1, 2 and 3 were determined by the manufacturer\u2019s in-house virus micro-neutralisation test standardized according to WHO guidance [13] and were expressed as the reciprocal of the dilution resulting in 50% inhibition.",
            "startOffset": 26135,
            "title": "Laboratory assays"
        },
        {
            "endOffset": 20890,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 20889,
                    "startOffset": 20884
                },
                "b0025": {
                    "endOffset": 20889,
                    "startOffset": 20884
                }
            },
            "secId": "s0005",
            "sentence": "In the absence of accepted correlate of protection for pertussis, the immunogenicity of dTap-IPVB was evaluated by comparison with historical pertussis efficacy data [4,5].",
            "startOffset": 20718,
            "title": "Introduction"
        },
        {
            "endOffset": 35568,
            "parents": [],
            "secId": "s0070",
            "sentence": "Accordingly, our pre-defined primary analysis was to compare the immune responses to the booster dose of dTap-IPVB given in this study against historical immunogenicity data from the original study that demonstrated clinical effectiveness for this combination of antigens.",
            "startOffset": 35296,
            "title": "Discussion"
        },
        {
            "endOffset": 27892,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Statistics"
                }
            ],
            "secId": "s0040",
            "sentence": "Secondary objectives were to describe the immunogenicity of both study vaccines in terms of seroprotection/seropositivity rates and GMCs/GMTs for all antigens, prior to and one month after booster vaccination; the percentage of participants with booster response to the pertussis and polio antigens; to describe the immune responses to the MMR vaccine in terms of seroconversion rates against mumps, measles and rubella, one month after booster vaccination; and to assess the safety and reactogenicity of the study vaccines in terms of solicited symptoms, unsolicited AEs and SAEs.",
            "startOffset": 27311,
            "title": "Analysis of immunogenicity"
        },
        {
            "endOffset": 35908,
            "parents": [],
            "secId": "s0070",
            "sentence": "GMCs for PT and FHA were higher for dTap-IPVB than dTap-IPVR, while the reverse was true for PRN.",
            "startOffset": 35811,
            "title": "Discussion"
        },
        {
            "endOffset": 30090,
            "parents": [],
            "secId": "s0055",
            "sentence": "387 children were enrolled and 385 were vaccinated: 255 in dTap-IPVB arm, 130 in dTap-IPVR group (Fig. 1).",
            "startOffset": 29984,
            "title": "Results"
        },
        {
            "endOffset": 35810,
            "parents": [],
            "secId": "s0070",
            "sentence": "All titres were significantly boosted but, as might be expected, with minor difference between the vaccines.",
            "startOffset": 35702,
            "title": "Discussion"
        },
        {
            "endOffset": 28733,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Statistics"
                }
            ],
            "secId": "s0045",
            "sentence": "Safety and reactogenicity of the study vaccines were assessed in terms of solicited symptoms (local and general), unsolicited symptoms and SAEs.",
            "startOffset": 28589,
            "title": "Safety"
        },
        {
            "endOffset": 20464,
            "parents": [],
            "secId": "s0005",
            "sentence": "The aim of this study was to generate evidence to support the use of dTap-IPVB in three to four year olds so it could potentially be used as a pre-school booster vaccine at this age.",
            "startOffset": 20282,
            "title": "Introduction"
        },
        {
            "endOffset": 31119,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "For the study\u2019s primary inferential analyses; at 30 days post booster vaccination the non-inferiority criteria for the upper bounds of the 95% CI of differences between comparator vaccines were met for all component antigens (i.e., seroprotection levels for diphtheria and tetanus, and GMCs ratio for polio and pertussis antigens) (Table 3).",
            "startOffset": 30778,
            "title": "Immunogenicity results"
        },
        {
            "endOffset": 31707,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "For all antigens, 30 days post dTap-IPV booster vaccination the proportions of seroprotected/seropositive children had risen to >99% indicating adequate serological response.",
            "startOffset": 31533,
            "title": "Immunogenicity results"
        },
        {
            "endOffset": 28578,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Statistics"
                }
            ],
            "refoffsets": {
                "b0080": {
                    "endOffset": 28577,
                    "startOffset": 28573
                }
            },
            "secId": "s0040",
            "sentence": "Given the absence of serologic correlates of protection against pertussis, an immuno-bridging approach was used to assess immune responses to pertussis antigens, by extrapolating the efficacy of a vaccine against pertussis as demonstrated in infants to an older age group, as previously described [16].",
            "startOffset": 28276,
            "title": "Analysis of immunogenicity"
        },
        {
            "endOffset": 33519,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "One SAE was reported during the whole clinical study duration; pneumonia requiring hospitalisation reported for one participant in the dTap-IPVB arm.",
            "startOffset": 33370,
            "title": "Safety results"
        },
        {
            "endOffset": 34869,
            "parents": [],
            "secId": "s0070",
            "sentence": "For diphtheria, although post-booster all children had antibody levels above threshold, GMCs were marginally higher for dTap-IPVR than dTap-IPVB but still 80-fold above the level considered protective.",
            "startOffset": 34668,
            "title": "Discussion"
        },
        {
            "endOffset": 26609,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0035",
                    "title": "Statistics"
                }
            ],
            "refoffsets": {
                "b0075": {
                    "endOffset": 26608,
                    "startOffset": 26604
                }
            },
            "secId": "s0040",
            "sentence": "The protocol pre-defined standard non-inferiority criteria [15].",
            "startOffset": 26545,
            "title": "Analysis of immunogenicity"
        }
    ],
    "docId": "S0264410X18303669",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "Robin.Marlow@bristol.ac.uk",
                "first": "Robin",
                "initial": "R.",
                "last": "Marlow"
            },
            {
                "email": "sherine.o.kuriyakose@gsk.com",
                "first": "Sherine",
                "initial": "S.",
                "last": "Kuriyakose"
            },
            {
                "email": "narcisa.x.mesaros@gsk.com",
                "first": "Narcisa",
                "initial": "N.",
                "last": "Mesaros"
            },
            {
                "email": "hhhlatt@hotmail.com",
                "first": "Htay Htay",
                "initial": "H.H.",
                "last": "Han"
            },
            {
                "email": "Richard.tomlinson@nhs.net",
                "first": "Richard",
                "initial": "R.",
                "last": "Tomlinson"
            },
            {
                "email": "s.faust@soton.ac.uk",
                "first": "Saul N.",
                "initial": "S.N.",
                "last": "Faust"
            },
            {
                "email": "matthew.snape@paediatrics.ox.ac.uk",
                "first": "Matthew D.",
                "initial": "M.D.",
                "last": "Snape"
            },
            {
                "email": "andrew.pollard@paediatrics.ox.ac.uk",
                "first": "Andrew J.",
                "initial": "A.J.",
                "last": "Pollard"
            },
            {
                "email": null,
                "first": "Adam",
                "initial": "A.",
                "last": "Finn"
            }
        ],
        "doi": "10.1016/j.vaccine.2018.03.021",
        "firstpage": "2300",
        "issn": "0264410X",
        "keywords": [
            "Child",
            "Preschool booster",
            "RCT",
            "UK",
            "dTap-IPV"
        ],
        "lastpage": "2306",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK"
    }
}